Side-by-side · Research reference

CJC-1295 (no DAC)vsFOXO4-DRI

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED15/51 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

01Mechanism of Action

Parameter

CJC-1295 (no DAC)

FOXO4-DRI

Primary target

Pituitary GHRH receptorTeichman 2006

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Pathway

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Downstream effect

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Feedback intact?

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

—

Origin

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

CJC-1295 (no DAC)

FOXO4-DRI

Standard dose

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

—

Frequency

1–2× daily (pre-sleep ± morning)

—

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Animal / mechanistic

Duration

8–12 weeks on / 4 off (anecdotal)

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

—

Half-life

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

—

Animal dose (mouse)

—

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

Frequency (animal)

—

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

Human equivalent (theoretical)

—

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

Route

—

SQ (animal)

No human route established.

Clinical status

—

No human trials completed

04Side Effects & Safety

Parameter

CJC-1295 (no DAC)

FOXO4-DRI

Injection site reaction

Erythema, mild pruritus

—

Flushing / headache

Common transient effect

—

Cortisol elevation

Minimal at standard doses

—

Prolactin elevation

Minimal

—

Glucose intolerance

Possible at high cumulative doses

—

IGF-1 elevation

Dose-dependent; monitor with chronic use

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Pregnancy / OB

Avoid

—

Pulmonary hypertension risk

—

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

Context-dependent toxicity

—

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

Off-target apoptosis

—

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

Immune perturbation

—

Senescent cells contribute to immune surveillance; clearance effects unknown

Human safety unknown

—

No clinical trials — toxicity profile in humans not established

Absolute Contraindications

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Relative Contraindications

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

05Administration Protocol

Parameter

CJC-1295 (no DAC)

FOXO4-DRI

1. Reconstitution

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

Subcutaneous injection used in rodent models. No human administration protocol exists.

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites.

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

3. Timing

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

5. Needle

29–31G, 4–8 mm insulin syringe.

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

06Stack Synergy

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998

FOXO4-DRI

— no documented stacks